Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Literature DB >> 17570067

Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Giovanna Aparecida Balarini Lima¹, Evelyn de Oliveira Machado, Cintia Marques Dos Santos Silva, Paulo Niemeyer Filho, Mônica Roberto Gadelha.

Abstract

Pituitary apoplexy is a rare and life-threatening clinical condition caused by hemorrhage and/or infarction of the pituitary gland or adenoma. Although pituitary apoplexy is usually spontaneous, it has been associated with numerous precipitating factors, such as bromocriptine use. However, reports of pituitary apoplexy during cabergoline therapy are scarce. We report three patients with cystic macroprolactinomas who developed pituitary apoplexy during cabergoline treatment.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 17570067 DOI： 10.1007/s11102-007-0046-6

Source DB: PubMed Journal: Pituitary ISSN： 1386-341X Impact factor: 4.107

55 in total

1. Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells.

Authors: H M Lloyd; J D Meares; J Jacobi
Journal: Nature Date: 1975-06-05 Impact factor: 49.962

2. Pituitary apoplexy: a review and reappraisal.

Authors: R L Rovit; J M Fein
Journal: J Neurosurg Date: 1972-09 Impact factor: 5.115

3. Pituitary apoplexy treated by transsphenoidal surgery. A clinicopathological and immunocytochemical study.

Authors: M J Ebersold; E R Laws; B W Scheithauer; R V Randall
Journal: J Neurosurg Date: 1983-03 Impact factor: 5.115

4. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

Authors: A Colao; A Di Sarno; F Sarnacchiaro; D Ferone; G Di Renzo; B Merola; L Annunziato; G Lombardi
Journal: J Clin Endocrinol Metab Date: 1997-03 Impact factor: 5.958

Review 5. Pituitary apoplexy.

Authors: C A Rolih; K P Ober
Journal: Endocrinol Metab Clin North Am Date: 1993-06 Impact factor: 4.741

6. Dopamine agonists and pituitary tumor shrinkage.

Authors: J S Bevan; J Webster; C W Burke; M F Scanlon
Journal: Endocr Rev Date: 1992-05 Impact factor: 19.871

7. A retrospective analysis of pituitary apoplexy.

Authors: D C Bills; F B Meyer; E R Laws; D H Davis; M J Ebersold; B W Scheithauer; D M Ilstrup; C F Abboud
Journal: Neurosurgery Date: 1993-10 Impact factor: 4.654

8. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis.

Authors: H Mori; S Mori; Y Saitoh; N Arita; T Aono; T Uozumi; H Mogami; K Matsumoto
Journal: Cancer Date: 1985-07-15 Impact factor: 6.860

9. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors: J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal: N Engl J Med Date: 1994-10-06 Impact factor: 91.245

10. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.

Authors: A Enjalbert; J Bockaert
Journal: Mol Pharmacol Date: 1983-05 Impact factor: 4.436

8 in total

Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

1. Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells.

2. Pituitary apoplexy: a review and reappraisal.

3. Pituitary apoplexy treated by transsphenoidal surgery. A clinicopathological and immunocytochemical study.

4. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

Review 5. Pituitary apoplexy.

6. Dopamine agonists and pituitary tumor shrinkage.

7. A retrospective analysis of pituitary apoplexy.

8. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis.

9. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

10. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.

Review 1. Management of cystic prolactinomas: a review.

2. Delayed identification of massive pituitary apoplexy in pregnancy: A case report.

3. Significance of surgical management for cystic prolactinoma.

Review 4. Apoplexy in nonfunctioning pituitary adenomas.

Review 5. Multidisciplinary Management of Pituitary Apoplexy.

6. Pituitary Adenoma Apoplexy in an Adolescent: A Case Report and Review of the Literature.

7. Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline.

8. Successful pregnancy in a female with a large prolactinoma after pituitary tumor apoplexy.